Tg Therapeutics's 15min Chart Shows RSI Overbought, KDJ Death Cross

Tg Therapeutics's 15-minute chart has triggered an RSI Overbought signal and a KDJ Death Cross at 09/22/2025 13:15. This indicates that the stock price has risen too rapidly and exceeds the level of fundamental support. Furthermore, the momentum of the stock price is shifting towards the downside, suggesting a potential decrease in the stock price.

TG Therapeutics (TGTX) has experienced significant technical challenges, as indicated by a 15-minute chart that triggered an RSI Overbought signal and a KDJ Death Cross on September 22, 2025, at 13:15. This suggests that the stock price has risen too rapidly and exceeds the level of fundamental support, potentially signaling a downturn in the stock's momentum. Despite these technical indicators, the company continues to receive positive analyst ratings and has seen a rise in its price target.

B. Riley Securities, a prominent investment firm, maintains a Buy rating for TG Therapeutics and recently raised its price target from $53.00 to $55.00. This adjustment reflects renewed confidence in the company's future performance, aligning with recent market evaluations and strategic developments TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].

TG Therapeutics is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received FDA approval for BRIUMVI, a treatment for adult patients with relapsing forms of multiple sclerosis (RMS). It is also developing several other promising therapies, including TG-1701, Azer-Cel, and TG-1801, which are currently in Phase 1 trials. The majority of TG Therapeutics' revenue comes from the sale of BRIUMVI in the United States, with additional sales in other countries TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].

Wall Street analysts have forecasted an average target price of $42.00 for TG Therapeutics, with a high estimate of $55.00 and a low estimate of $11.00. This implies an average upside of 29.91% from the current price of $32.33. The consensus brokerage recommendation is "Outperform," reflecting the positive sentiment among financial analysts TGTX: B. Riley Securities Raises Price Target on TG Therapeutics | TGTX Stock News^[1].

Additionally, new options for TG Therapeutics began trading this week, with the May 2026 expiration. Investors have the opportunity to sell put and call contracts, with potential premiums and yield boosts. The put contract at the $32.00 strike has a current bid of $5.80, while the call contract at the $34.00 strike has a current bid of $6.30. These contracts represent an attractive alternative for investors interested in the company's future prospects Interesting TGTX Put And Call Options For May 2026^[2].

Despite the technical challenges, TG Therapeutics remains a favored investment among analysts, with a strong growth outlook and a diverse pipeline of innovative therapies. However, investors should closely monitor the company's technical indicators and consider the potential risks associated with the recent price movements.